- Previous Close
71.40 - Open
72.31 - Bid 72.21 x 200
- Ask 72.40 x 700
- Day's Range
71.24 - 72.67 - 52 Week Range
21.92 - 80.53 - Volume
1,251,808 - Avg. Volume
2,039,217 - Market Cap (intraday)
12.42B - Beta (5Y Monthly) 1.11
- PE Ratio (TTM)
-- - EPS (TTM)
-5.41 - Earnings Date Oct 24, 2024 - Oct 28, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
87.63
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
www.insmed.comRecent News: INSM
View More
Performance Overview: INSM
Trailing total returns as of 10/4/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: INSM
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: INSM
View MoreValuation Measures
Market Cap
12.42B
Enterprise Value
12.39B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
32.50
Price/Book (mrq)
319.99
Enterprise Value/Revenue
37.71
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-244.27%
Return on Assets (ttm)
-24.77%
Return on Equity (ttm)
--
Revenue (ttm)
328.6M
Net Income Avi to Common (ttm)
-802.69M
Diluted EPS (ttm)
-5.41
Balance Sheet and Cash Flow
Total Cash (mrq)
1.25B
Total Debt/Equity (mrq)
3,544.14%
Levered Free Cash Flow (ttm)
-306.68M
Research Analysis: INSM
View MoreCompany Insights: INSM
INSM does not have Company Insights
Research Reports: INSM
View MoreDaily – Vickers Top Buyers & Sellers for 11/03/2022
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 01/10/2022
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 11/04/2021
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.